Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.

@article{Eyre2017ComparingTI,
  title={Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.},
  author={Harris A. Eyre and Prabha Siddarth and Natalie Cyr and Hongyu Yang and Steve W. Cole and Malcolm P Forbes and Helen Lavretsky},
  journal={Pharmacopsychiatry},
  year={2017},
  volume={50 6},
  pages={
          256-263
        }
}
Vilazodone is a novel antidepressant agent that combines selective serotonin (5-HT) reuptake inhibitor (SSRI) activity and 5-HT(1A) receptor partial agonist activity. A pilot study was conducted to compare vilazodone (novel compound) and paroxetine (gold standard) on antidepressant effects, tolerability, and inflammation and immune modulation. A 12-week, double-blind, randomized clinical trial was conducted with 56 nondemented older adults diagnosed with major depressive disorder (MDD). Between… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Clinical Global Impressions (CGI). In: Services UDoHaH.ed. ECDEU Assessment Manual for Psychopharmacology. Rockville: Alcohol drug abuse and mental health administration

  • W. Guy
  • NIMPH Psychopharmacology Research Branch;
  • 1976
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A phase-specific neuroimmune model of clinical depression

VIEW 2 EXCERPTS

Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression.

A functional genomic perspective on human well-being.